Systematic review evaluates therapeutic drug monitoring's clinical utility in optimizing beta-lactam dosing for deep infections, suggesting a need for better trials.
Current evidence supporting beta-lactam antibiotic TDM in deep-seated infections is limited by methodological heterogeneity and poor study quality. Well-designed trials are needed to establish the clinical utility of TDM in this setting.
No takes yet. Share an insight, caveat, or question.
Vale et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: